Gene · 6281
NIH grants2,552
NIH grants whose papers are about the gene, through NIH's grant-paper links.
661 to 680 of 2,552
Download this page as JSON| Grant | Title | S100A10 papers | Newest fiscal year |
|---|---|---|---|
| P30NS045892 | UNC Neuroscience Center Research Cores | 1 | 2022 |
| P50CA062924 | SPORE in Gastrointestinal Cancers | 1 | 2022 |
| R00HL136784 | The racial disparity in platelet PAR4 signaling enhances thrombus formation | 1 | 2022 |
| R01AG056477 | Education, socioeconomic status and Aging: transitions from multimorbidity to functional limitations and mortality | 1 | 2022 |
| R01AG056699 | Impact of Heightened UPR Activation on Inflammasome Responses to Influenza and Secondary Streptococcus pneumoniae Infection in Aged Lung | 1 | 2022 |
| R01AI136972 | Genetic regulation and immunological function of ERAP2 haplotypes | 1 | 2022 |
| R01AI137567 | Host response and liver disease in a hepatitis C-like virus rat model | 1 | 2022 |
| R01AI139473 | Novel adjuvant to boost humoral and cellular immune responses against influenza | 1 | 2022 |
| R01AI140705 | SFTSV nonstructural protein NSs-mediated immunopathogenesis | 1 | 2022 |
| R01AI140718 | Genetic evolution, pathogenesis and immune responses in mother to child transmission of ZIKV | 1 | 2022 |
| R01AI147890 | Retrovirus Structure and Assembly with Inositol Phosphates | 1 | 2022 |
| R01CA101795 | Novel Strategies for Intervention of Inflammatory Diseases and Cancer | 1 | 2022 |
| R01CA167291 | Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations | 1 | 2022 |
| R01CA211098 | Thrombin-dependent mechanisms of pancreatic ductal adenocarcinoma disease | 1 | 2022 |
| R01CA218230 | Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsies | 1 | 2022 |
| R01CA220273 | Investigating serum exosomal annexin A2 in promoting aggressive TNBC in African American women | 1 | 2022 |
| R01CA222147 | Theory and methods for mediation and interaction | 1 | 2022 |
| R01CA222467 | Impact of microRNA processing on EMT of ovarian cancer cells | 1 | 2022 |
| R01CA225680 | Role of CPT1A as a lysine succinyltransferase in tumorigenesis | 1 | 2022 |
| R01CA227737 | BRAVE hydrogels for interrogating cell-matrix interactions in pancreatic desmoplasia | 1 | 2022 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6281/grants?page=34